UPDATE: RXi Pharma Says Purchase Of MirImmune Resulted In $1.6M Increase To Acquired In-Process R&D Expense, Corresponding $1.6M Income Tax Benefit From Reduction Of Valuation Allowance Which Were Not Accounted For Properly